Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance study of [14C]RAY1216 in healthy Chinese males
NCT06362460Phase 1Completed
- Sponsor
- Raynovent Biotech
- Start
- Sep 2023
- Primary completion
- Nov 2023
- Modality
- Covalent Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of leritrelvir in coronavirus disease 2019 (COVID-19), sponsored by Raynovent Biotech. Primary endpoints: Total radioactivity in plasma PK up to 7 days and Mass balance recovery of total radioactivity in all (urine, faeces) amount excreted up to 14 days. Started Sep 2023; status: completed.
02
Drugs
leritrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06362460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06362460.